Dawn Svoronos

CIK: 0001574579

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (12.5%)

Derivative conversions

Awards (A)5 (31.3%)

Compensation grants

Other (G, F, J, C, D, …)9 (56.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

XENE

Xenon Pharmaceuticals Inc.

Director

ADVM

Adverum Biotechnologies, Inc.

Director

SLRN

ACELYRIN, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (16 total)

XENE
Xenon Pharmaceuticals Inc.
Sep 1, 2026
Exercise(M)
Direct
5.1K shares at avg. $8.15$42K
XENE
Xenon Pharmaceuticals Inc.
Jun 3, 2026
Award(A)
Restricted Share Units
Direct
1.6K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 3, 2026
Award(A)
Share Option (Right to Buy)
Direct
10.5K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 1, 2026
Tax Payment(F)
Direct
1.4K shares at avg. $53.41$76K
XENE
Xenon Pharmaceuticals Inc.
Jun 1, 2026
Exercise(M)
Direct
2.6K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
10.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
10.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4.5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Tender Offer(U)
Direct
5K shares-
ADVM
Adverum Biotechnologies, Inc.
Dec 9, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
4K shares-
ADVM
Adverum Biotechnologies, Inc.
Jun 17, 2025
Award(A)
Stock Option (Right to Buy)
Direct
10.5K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2025
Award(A)
Share Option (Right to Buy)
Direct
17K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2025
Award(A)
Restricted Share Units
Direct
2.6K shares-
SLRN
ACELYRIN, Inc.
May 21, 2025
Disposition(D)
Direct
15K shares-

		Type	Shares	Price		Ownership
Sep 1, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	5,144	$8.15	$41,924	Direct
Jun 3, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	1,593	-	-	Direct
Jun 3, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	10,507	-	-	Direct
Jun 1, 2026	XENE Xenon Pharmaceuticals Inc.	Tax Payment(F)	1,416	$53.41	$75,629	Direct
Jun 1, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	2,645	-	$0	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	10,520	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	10,450	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,000	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,500	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,000	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Tender Offer(U)	5,000	-	-	Direct
Dec 9, 2025	ADVM Adverum Biotechnologies, Inc.	Disposition(D) Stock Option (Right to Buy)	4,000	-	-	Direct
Jun 17, 2025	ADVM Adverum Biotechnologies, Inc.	Award(A) Stock Option (Right to Buy)	10,450	-	-	Direct
Jun 5, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	17,012	-	-	Direct
Jun 5, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	2,645	-	-	Direct
May 21, 2025	SLRN ACELYRIN, Inc.	Disposition(D)	15,000	-	-	Direct

1-16 of 16 transactions

About Svoronos Dawn

Svoronos Dawn (SEC CIK 0001574579) files insider reports with the SEC as Director of Xenon Pharmaceuticals Inc. (XENE), Director of Adverum Biotechnologies, Inc. (ADVM) and Director of ACELYRIN, Inc. (SLRN).

Signal8 holds 6 ownership filings by Svoronos Dawn, all Form 4s, filed between May 23, 2025 and Sep 3, 2026. Those filings report 16 transactions, from May 21, 2025 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Svoronos Dawn's filings is in BURNABY.

Recent filings by Svoronos Dawn

Sep 1, 2026: Option exercise of XENE shares (Form 4, code M).
Jun 3, 2026: Grants or awards of XENE derivative securities (2 lines, Form 4, code A).
Jun 1, 2026: Tax withholding of XENE shares (Form 4, code F).
Jun 1, 2026: Option exercise of XENE shares (Form 4, code M).
Dec 9, 2025: Disposition to issuer transactions of ADVM derivative securities (5 lines, Form 4, code D).

Other insiders filing for Xenon Pharmaceuticals Inc. (XENE)

Kelly Thomas Patrick, Chief Financial Officer
MORTIMER IAN, PRESIDENT & CEO
GANNON STEVEN, Director
PATOU GARY, Director
Cannon Gillian, Director
Machado Patrick, Director

How to read Form 4 transaction codes